BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
34.05
-1.24 (-3.51%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close35.29
Open33.24
Bid32.31 x 1300
Ask39.95 x 4000
Day's Range31.58 - 34.75
52 Week Range24.54 - 39.44
Volume19,874,368
Avg. Volume7,293,067
Market Cap47.118B
Beta (3Y Monthly)0.96
PE Ratio (TTM)89.84
EPS (TTM)0.38
Earnings DateJan 30, 2019 - Feb 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.30
Trade prices are not sourced from all markets
  • Associated Press12 hours ago

    Target, Boston Scientific and Kohl's fall; Campbell jumps

    Stocks that moved substantially or traded heavily Tuesday: Target Corp., down $8.12 to $69.03 The retailer's profit fell short of Wall Street expectations as it invested more in its stores and its online ...

  • Moody's13 hours ago

    Boston Scientific Corporation -- Moody's affirms Boston Scientific's Baa2 senior unsecured rating, stable outlook

    Moody's Investors Service ("Moody's") today affirmed Boston Scientific Corporation's Baa2 senior unsecured ratings and its Prime-2 commercial paper rating. The affirmation of the ratings follows Boston Scientific's announcement that it has reached an agreement to acquire BTG Plc, a UK-based medical products company. Under the terms of the offer, Boston Scientific will acquire BTG for approximately GBP 3.3 billion ($4.2 billion at current exchange rates).

  • Reuters15 hours ago

    Boston Scientific backs BTG offer with £3.3bn bridge loan

    US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn bridge loan from Barclays Bank. The bridge loan covers the full amount of the cash consideration and satisfies the certain funds requirements of the UK Takeover Code. The acquisition, which has been unanimously approved by the boards of directors of Boston Scientific and BTG, is expected to be carried out through an English court-sanctioned scheme of arrangement, and is expected to close in the first half of 2019.

  • TheStreet.com18 hours ago

    Boston Scientific to Buy Britain's BTG for $4.2 Billion

    Boston Scientific Corp. on Tuesday agreed to buy British healthcare company BTG plc in a $4.2 billion deal. The Marlborough, Mass.-based medical device maker offered $10.77 for each BTG share, representing a premium of 36.

  • Boston Scientific Plunges After $4.2 Billion Medical Device Deal
    Bloomberg19 hours ago

    Boston Scientific Plunges After $4.2 Billion Medical Device Deal

    While the deal will give Boston Scientific new products for the treatment of cancer and other disorders, it will add to the U.S. company’s debt. Boston Scientific “has takeout speculation in shares and thus doing a deal will be a perceived negative as far as the stock is concerned,” Holz said in a note to clients. Boston Scientific, a maker of stents that hold open damaged blood vessels, will pay 840 pence in cash per share, a 37 percent premium over BTG’s Monday closing price, according to a statement.

  • Boston Scientific to buy British medical device firm for $4.2B
    American City Business Journals19 hours ago

    Boston Scientific to buy British medical device firm for $4.2B

    One of the state's biggest medical device companies is getting even bigger through a global acquisition.

  • Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
    Zacks21 hours ago

    Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm

    Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.

  • Financial Times21 hours ago

    [$$] Stocks to watch: BTG, JD Wetherspoon, Apple, Skyworks, Teradyne

    Boston offered 840p in cash for BTG, a premium of 36.6 per cent to its Monday closing price. Analysts saw a counterbid as unlikely given what Jefferies called BTG’s “somewhat eclectic product mix” and the competition risks facing CroFab, its top-selling rattlesnake antivenom. Panmure Gordon called the price “fair, though not generous” at 15.2 times 2019 earnings, against the sector average for takeovers of 24 times earnings.

  • CNBC21 hours ago

    Stocks making the biggest move premarket: TGT, BBY, KSS, LOW, MDT & more

    Check out the companies making headlines before the bell: Target TGT – The retailer earned an adjusted $1.09 per share for the third quarter , 3 cents a share below estimates. Revenue exceeded forecasts, however, and comparable-store sales were up 5.

  • GE’s Healthcare Unit Spin-Off to Maximize Shareholders’ Wealth
    Market Realist21 hours ago

    GE’s Healthcare Unit Spin-Off to Maximize Shareholders’ Wealth

    General Electric’s (GE) Healthcare segment, which offers medical imaging and information technologies, biopharmaceutical manufacturing technologies, and patient monitoring systems, is one of the company’s better-performing units and is the fourth-largest contributor to its total revenue.

  • Reuters22 hours ago

    Boston Scientific builds medical tech with $4.2 billion BTG deal

    U.S. medical device maker Boston Scientific Corp (BSX.N) has agreed to buy Britain's BTG Plc (BTG.L) for 3.3 billion pounds in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.

  • Reuters22 hours ago

    Boston Scientific builds medical tech with $4.2 billion BTG deal

    U.S. medical device maker Boston Scientific Corp has agreed to buy Britain's BTG Plc for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.

  • Brexit Makes a $4.2 Billion Black Friday Bargain
    Bloomberg22 hours ago

    Brexit Makes a $4.2 Billion Black Friday Bargain

    Boston Scientific Corp. has seen its chance and agreed to buy London-based BTG Plc for 3.3 billion pounds ($4.2 billion). If the deal is consummated, the British maker of medical devices will join the growing list of internationally-flavored U.K. companies falling prey to overseas bidders. This has been a rough year for BTG.

  • The Wall Street Journal22 hours ago

    [$$] Boston Scientific Acquires U.K.'s BTG for $4.2 Billion

    Corp. on Tuesday said it had agreed to buy British health-care firm BTG PLC for £3.3 billion ($4.24 billion), bolstering its presence in the growing field of interventional medicine. The Marlborough, Mass.-based medical devices maker said it would pay 840 pence a share in cash for BTG, a 37% premium to the U.K.-listed company’s closing price Monday. BTG’s shares jumped 33% on the news.

  • TheStreet.com23 hours ago

    FAANGs, Retail, Housing, Boston Scientific & Renault - Five Things You Must Know

    U.S. listed tech stocks extended their slump in pre-market trading Tuesday, with Apple looking to slide into bear market territory, as investors continue to dump the so-called FAANG stocks amid persistent concerns over consumer demand, U.S.-China trade talks and rising interest rates. Apple shares were marked 1.4% lower in pre-market trading Tuesday, indicating an opening bell price of $183.25 each, a move that would take the decline since its October 3 close past 20% Nvidia shares, which have fallen more than 27% over the past week alone, are indicated to slide another 2.8% to 140.60 each. , which has fallen nearly 40% since late July amid a host of data privacy, corporate governance and profitability concerns, was marked 1.2% lower in pre-market trading, indicating an opening bell price of $130 each.

  • The Wall Street Journalyesterday

    [$$] Boston Scientific Agrees £3.3 Bln BTG Takeover

    Boston Scientific has agreed a takeover bid for U.K. specialty health-care company BTG in a deal worth £3.3 billion.

  • The Wall Street Journalyesterday

    [$$] Boston Scientific Agrees GBP3.3 Bln Takeover Bid for BTG

    Boston Scientific said Tuesday that it has agreed to a takeover bid for U.K. specialty health-care company BTG in a deal worth 3.3 billion pounds ($4.23 billion).

  • Reutersyesterday

    Boston Scientific offers to buy UK's BTG for about $4.24 billion

    U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash. The offer of 840 pence in cash per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday. BTG said it plans to recommend the deal to its shareholders as it considers the terms to be fair and reasonable.

  • PR Newswireyesterday

    Boston Scientific Announces Recommended Offer to Acquire BTG plc.

    The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B.

  • Financial Timesyesterday

    [$$] Anti-venom maker BTG provides £3.3bn antidote to the Faangs

    , were spiking 36 per cent on Tuesday morning — partly because it makes a snakebite cure. At 840p a share, this was 37 per cent higher than BTG’s closing price on Monday, and 51 per cent above its weighted average share price over the past three months.

  • Financial Timesyesterday

    [$$] Boston Scientific to buy rattlesnake bite drug group BTG for £3.3bn

    The deal will see Boston Scientific pick up the jumble of healthcare products owned by BTG, which has spent the past few years reducing its reliance on an expensive rattlesnake bite antidote that faces increased competition. It also comes after executive pay criticism against Dame Louise Makin, BTG’s chief executive, over future stock awards and bonus arrangements put in place for the company’s former finance director. Last month, BTG chairman Garry Watts announced his intention to retire by the end of the year.

  • Baxter International: Analysts Remain Bullish on the Stock
    Market Realist2 days ago

    Baxter International: Analysts Remain Bullish on the Stock

    In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.

  • Analyzing Baxter International’s Operational Performance
    Market Realist5 days ago

    Analyzing Baxter International’s Operational Performance

    Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.

  • Baxter International: Why Investors Are Interested
    Market Realist5 days ago

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.

  • Boston Scientific planning up to $150M in annual cuts, 'limited' layoffs
    American City Business Journals5 days ago

    Boston Scientific planning up to $150M in annual cuts, 'limited' layoffs

    Marlborough-based Boston Scientific will make changes to its supply chain network and anticipates some layoffs over the next few years, according to a federal filing on Thursday.